GlassScriptPhysician profile
Kimberly Ku
NPI 1609214063
$42,138.82
in general payments reported to CMS, 2019-2025
37 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.75 · 2021: $1,974 · 2022: $9,298 · 2023: $447 · 2024: $8,185 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Honoraria: $3,700 · Travel and Lodging: $1,563 · Food and Beverage: $982 · Education: $71.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,469.50 |
| Honoraria | $3,700.00 |
| Travel and Lodging | $1,562.90 |
| Food and Beverage | $982.06 |
| Education | $71.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,573.21 | 2022-2025 | Imfinzi, Tagrisso |
| Gilead Sciences, INC. | $4,087.86 | 2021-2025 | Trodelvy |
| Exelixis INC. | $3,490.45 | 2025 | Cabometyx |
| Geron Corporation | $2,930.25 | 2025 | Imetelstat |
| Genzyme Corporation | $2,440.00 | 2022 | |
| Daiichi Sankyo INC. | $2,266.25 | 2022-2024 | |
| Abbvie INC. | $1,827.50 | 2024-2025 | |
| Beigene USA, INC. | $1,625.00 | 2024 | Tevimbra |
| Novocure INC. | $1,625.00 | 2025 | Optune Lua (Novottf-200t) |
| Janssen Global Services, LLC | $1,560.00 | 2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Seagen INC. | $1,225.00 | 2022 | |
| Masimo Corporation | $1,132.00 | 2025 | |
| Incyte Corporation | $860.00 | 2024 | Jakafi |
| Janssen Scientific Affairs, LLC | $390.00 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dr.Reddy'S Laboratories,INC. | $230.00 | 2024 | |
| Tersera Therapeutics LLC | $190.00 | 2023 | |
| Mckesson Medical-Surgical Minnesota Supply, INC | $180.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $159.81 | 2022-2023 | |
| Cardinal Health 110 LLC | $125.00 | 2025 | |
| Menarini Silicon Biosystems, INC. | $100.00 | 2023 | Cellsearch |
| Tempus Ai, INC | $92.23 | 2024 | |
| Pfizer INC. | $87.36 | 2022-2025 | |
| Astellas Pharma US INC | $58.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.22 | 2022-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $49.20 | 2022-2023 | Imbruvica |
| Tosoh Bioscience, INC. | $48.00 | 2019 | |
| Adaptive Biotechnologies Corporation | $42.71 | 2021-2022 | |
| Macrogenics, INC. | $39.00 | 2022 | |
| Genentech USA, INC. | $31.63 | 2019-2022 | |
| Celgene Corporation | $25.48 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2023 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $18.13 | 2022 | |
| Verastem, INC. | $17.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.